MedTrace Logo

SCN2A Polymorphisms Are Associated With Response to Valproic Acid in Paediatric Population(Pakistan)

NCT06674070 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2024-11-05

No results posted yet for this study

Summary

The goal of this Observational study was to identify the effect of SCN2A gene polymorphism in the Paediatric epileptic Pakistani population. The main question it aims to answer is:

to evaluate the effect of this genetic polymorphism on the clinical efficacy of Valproic acid

Participants were prescribed Valproic acid after diagnosis of epilepsy.

Conditions

Interventions

GENETIC

Valproic Acid

syrup/ tablet EPIVAL (250mg

Sponsors & Collaborators

  • Riphah International University

    lead OTHER

Principal Investigators

  • Sughra Kanwal, MBBS · Riphah International University

Eligibility

Min Age
1 Month
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2024-07-31
Completion
2024-08-31

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06674070 on ClinicalTrials.gov